Tumoral melanosis (TM) is a rare entity thought to result from the complete regression of melanoma. Clinically, TM resembles malignant melanocytic lesions, presenting as hyperpigmented flat or papulonodular lesions. Histologically, TM lacks melanocytes, instead showing inflammation, fibrosis, and melanophages. Diagnosing melanoma without melanocytes is challenging, and TM may also represent other regressed benign or malignant pigmented lesions. This study retrospectively analyzed 12 TM cases focusing on the clinical course, management, and potential for malignancy. Among the cases, 50% were associated with advanced or metastatic melanoma, supporting TM's potential as a regressed melanoma. Conversely, in 50% of cases, TM occurred without primary or metastatic melanoma, suggesting possible regression of a benign or malignant epithelial lesion such as pigmented basal cell carcinoma (BCC) or seborrheic keratosis (SK) or confinement of melanoma by the immune system. Management included surgical excision and follow-up similar to that of melanoma. Sentinel lymph node biopsy (SLNB) was selectively performed based on clinical suspicion and multidisciplinary team discussions. In conclusion, TM should be considered potentially regressed melanoma, especially in patients with high disease burden, and the possibility of derivation from high-grade melanomas must always be considered. Given the inability to distinguish TM from completely regressed melanoma, clinicians must remain vigilant and suspect this origin during staging and follow-up. Comprehensive management and close monitoring are crucial to address TM's clinical implications.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13555-025-01363-9DOI Listing

Publication Analysis

Top Keywords

regressed melanoma
12
melanoma
9
tumoral melanosis
8
benign malignant
8
metastatic melanoma
8
melanosis case
4
case series
4
series rare
4
clinical
4
rare clinical
4

Similar Publications

Tumoral Melanosis: A Case Series of a Rare Clinical Entity.

Dermatol Ther (Heidelb)

February 2025

Department of Dermatology, University of Brescia, Piazzale Spedali Civili 1, Brescia, Italy.

Tumoral melanosis (TM) is a rare entity thought to result from the complete regression of melanoma. Clinically, TM resembles malignant melanocytic lesions, presenting as hyperpigmented flat or papulonodular lesions. Histologically, TM lacks melanocytes, instead showing inflammation, fibrosis, and melanophages.

View Article and Find Full Text PDF

Melanoma is a malignant proliferation of melanocytes originating from neural crest cells. Gallbladder melanoma is typically reported as a metastatic disease involving the adjacent liver. Thus, isolated gallbladder melanoma must be either a primary tumor originating within the gallbladder without evidence of metastasis or an isolated metastatic lesion from an unknown or regressed primary site.

View Article and Find Full Text PDF

Background: Cutaneous melanoma is the leading cause of death from cutaneous malignancy and tends to metastasize lymphatically and hematogenously to the lung, liver, brain, and bone; it is a rare source of metastatic disease to the eye. Herein we provide a case report of cutaneous melanoma metastatic to the ciliary body and choroid involving clinical examination, slit lamp photography, and B-scan ultrasonography.

Result: A 55-year-old female with known metastatic cutaneous melanoma presented with pain, a large ciliochoroidal mass, visual decline, and diffuse intraocular inflammation.

View Article and Find Full Text PDF

The absence of telomerase leads to immune response and tumor regression in zebrafish melanoma.

Cell Rep

December 2024

Institute for Research on Cancer and Aging of Nice (IRCAN), CNRS UMR7284, INSERM U1081, Université Côte d'Azur, 06107 Nice, France; Instituto Gulbenkian de Ciência, 2780-156 Oeiras, Portugal. Electronic address:

Most cancers re-activate telomerase to maintain telomere length and thus acquire immortality. Activating telomerase promoter mutations are found in many cancers, including melanoma. However, it is unclear when and if telomerase is strictly required during tumorigenesis.

View Article and Find Full Text PDF

Withaferin-A induced vimentin S56 phosphorylation dissociates NEDD9 signaling loop to regress progressive metastatic melanoma into lung adenocarcinoma.

Chem Biol Interact

January 2025

Molecular Biomedicine Laboratory, Postgraduate Department of Studies and Research in Biotechnology, Sahyadri Science College, Kuvempu University, Shivamogga, 577203, Karnataka, India. Electronic address:

Article Synopsis
  • Metastasis is a complicated disease that relies on specific protein interactions, such as Vimentin and NEDD9, which are crucial for cancer progression and treatment resistance.
  • Withaferin A (WFA) is a natural compound thought to target Vimentin, potentially offering a way to inhibit metastasis, although its complete mechanism is still not clear.
  • Research has utilized various techniques, including gene expression analysis and protein interaction assays, to demonstrate that targeting the Vimentin-NEDD9 interaction with WFA can reduce melanoma spread to the lungs, highlighting its potential as a therapeutic approach.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!